About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

The 5 Most Interesting Analyst Questions From Pfizer’s Q1 Earnings Call

PFE Cover Image

Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined expense control, even as revenue declined. CEO Albert Bourla credited robust execution in key therapeutic areas, particularly oncology and internal medicine, for helping offset lower sales from COVID-related products. CFO Dave Denton highlighted the impact of productivity programs and a refined commercial approach, noting that adjusted operating expenses fell meaningfully due to ongoing cost realignment. Management acknowledged external pressures, including U.S. policy changes and lower COVID demand, but pointed to operational efficiency as a key factor supporting profitability.

Is now the time to buy PFE? Find out in our full research report (it’s free).

Pfizer (PFE) Q1 CY2025 Highlights:

  • Revenue: $13.72 billion vs analyst estimates of $13.94 billion (7.8% year-on-year decline, 1.6% miss)
  • Adjusted EPS: $0.92 vs analyst estimates of $0.67 (36.5% beat)
  • The company reconfirmed its revenue guidance for the full year of $62.5 billion at the midpoint
  • Management reiterated its full-year Adjusted EPS guidance of $2.90 at the midpoint
  • Market Capitalization: $136.3 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call

  • Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure. CFO Dave Denton reiterated the dividend’s priority in capital allocation and expressed confidence in cost management supporting this commitment.

  • Evan Seigerman (BMO Capital Markets): Inquired about Pfizer’s obesity pipeline strategy after discontinuing a candidate. Chief Scientific Officer Chris Boshoff explained the focus on differentiated, more tolerable oral therapies and the pursuit of both internal and external opportunities.

  • Tim Anderson (Bank of America): Questioned the likelihood and scope of sector-specific tariffs and potential impacts on manufacturing. CEO Albert Bourla shared insights from government discussions, highlighting distinctions between friendly and adversary countries and Pfizer’s contingency planning.

  • Trung Huynh (UBS): Sought clarity on the timing and magnitude of cost savings. Denton said most additional identified savings would be realized post-2025, with R&D productivity improvements expected to be reinvested in the pipeline.

  • Geoff Meacham (Citi): Asked about business development priorities and the impact of LOEs. Bourla and Chief Strategy Officer Andrew Baum emphasized the focus on building sustainable franchises through both internal R&D and disciplined acquisitions.

Catalysts in Upcoming Quarters

In the months ahead, the StockStory team will be watching (1) progress on late-stage clinical trial readouts and regulatory decisions in oncology and vaccines, (2) the impact of cost-saving initiatives on operating margins as Pfizer approaches upcoming patent expirations, and (3) developments in global trade policy and tariffs that could affect supply chain resilience. Execution on business development and timely new product launches will also be important markers for future performance.

Pfizer currently trades at $24, up from $23.03 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.